Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUPERNOVA
2024-512554-15-00Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial of sipavibart in coronavirus disease 2019 (COVID-19) (4 cohorts), sponsored by AstraZeneca. Primary endpoints: Safety – adverse events, Prophylactic efficacy against symptomatic COVID-19 and 1 more. Started Jul 2024; status: completed.
02
Drugs
sipavibart
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2024-512554-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512554-15-00.